This invention related to a method for diagnosing a skin displaying signs of aging, based on measuring the level of expression of the gene encoding the IDE. The present invention also relates to a method for the cosmetic treatment of skin. This invention also relates to a method for identifying a compound for reducing the signs of the aging of the skin as well as a kit.

The present disclosure relates generally to methods of treating human patients suffering from a liver disease or condition. The disclosure also provides diagnostic methods for determining the stage or status of the liver disease or condition and monitoring methods for assessing the effectiveness of a treatment, using serum protein, metabolites or bile acid markers.

A biosensor for detecting a biomarker in a bodily fluid, secretion or exudation is described that includes a first electrode, a second electrode, an electrode coating and a mechanical electrode stabilizer. The biomarker is an enzyme catalyzing a chemical reaction in which a singularity or plurality of constituents of the electrode coating are chemically altered by the breaking of covalent chemical bonds when being in contact with the same. The electrode coating can be a natural or synthetic substrate of the biomarker. The first electrode and the second electrode are electrically conductive and are kept in a substantially constant and uniform distance from each other by means of the mechanical electrode stabilizer. The exposed electrically conductive surface of at least one of the first electrode and the second electrode are substantially fully covered by the electrode coating.

Aspects of the present disclosure include methods of producing a circulating analyte profile of a subject. The methods include contacting a blood sample from a subject with a panel of probes for specific binding to analytes, and detecting the presence or absence of binding of the analytes to probes of the panel of probes. Also provided are sensor devices including a panel of capture probes and useful, e.g., for practicing the methods of the present disclosure.

The present disclosure provides methods for the detection of multiple analytes using a single solid phase. The present disclosure also relates to the preparation of solid phases that include receptacles having affixed thereto antibodies directed to at least two different analytes. The methods of the present disclosure can be used, for example, for the quantitative detection of analytes in a sample and the measurement thereof.

Provided are methods and related kits for detection of early stage pancreatic ductal adenocarcinoma. Also provided are methods for treating a patient susceptible, or suspected of being susceptible, to pancreatic ductal adenocarcinoma.

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

Disclosed are methods for predicting, inhibiting, and treating chronic kidney disease (CKD) in a subject that that is preparing to undergo a liver transplant. The methods may include detecting a protein biomarker in a serum sample from the subject prior to the subject being administered a liver transplant procedure and/or after the subject has been administered the liver transplant procedure. Suitable protein markers for the disclosed methods may include but are not limited to osteopontin (OPN) and/or tissue inhibitor of metalloproteases 1 (TIMP1).

It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G.sub.0/G.sub.1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G.sub.0/G.sub.1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.